The Hematologist

banner image

New Podcast: Beat AML Trial Update

Drs. John Byrd, Elizabeth Raetz and Eytan Stein discuss the trial's design, rationale, and results, as well as its significance in developing a precision medicine approach to treat AML.

Play here
banner image

Testosterone Therapy: Risk Factor for VTE?

Dr. Moll reviews testosterone therapy in patients diagnosed with VTE as a contributing VTE risk factor.

Read more
banner image

The Epitranscriptome in Leukemia

Dr. Abdel-Wahab studies the role of the epitranscriptome in the context of normal and malignant hematopoiesis.

Read more
Current Issue Static Feature

Current Issue

March/April 2017              
Volume 14, Issue 2

Read current issue

President's Column

Presidents Column - Kenneth AndersonKraft Family Professor of Medicine, Harvard Medical School; Director Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center Dana-Farber Cancer Institute, Boston, MA
Way to Make a Statement: Government Policy and ASH
March 1, 2017

Dr. Kenneth Anderson offers insight into the Society's official policy statements.

View all president's column articles

  • ACA Update
    March 21, 2017

    The House of Representatives released legislation, titled the “American Health Care Act,” to repeal the Affordable Care Act.  As written, ASH has serious concerns that this legislation will reduce overall access to coverage and treatment and would greatly impact patients with hematologic diseases and disorders.

  • DEA Eliminates Grace Period for Registration Renewal
    December 21, 2016

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model
    December 20, 2016

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

  • NHLBI Small Business Innovation Research Funding Opportunity Fosters Production of Blood Cells From Stem Cells
    November 23, 2016

    ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.

View all Policy News